Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Conn. High Court Snapshot: $13.2M Estate Tax Tops January No Photo Available

Aaron Keller

The state of Connecticut's attempt to collect $13.2 million in taxes from the estate of a healthcare executive and a hospital's potent... (more story)

High Court's Med Mal Ruling Won't Spark Rise In Suits No Photo Available

Y. Peter Kang

The U.S. Supreme Court's recent ruling that a Delaware medical malpractice statute can't be enforced in federal court won't cause a no... (more story)

Justices To Clarify What's Fair Game With 'Skinny Labels' No Photo Available

Ryan Davis

A new U.S. Supreme Court patent case that will require the justices to spell out what generic-drug makers can say when marketing drugs... (more story)